JB Chemicals & Pharmaceuticals (506943) Q1 25/26 earnings summary

Executive summary

• Torrent Pharma announced acquisition of a 46.39% stake in JB Pharma for INR 11,917 crore, triggering a mandatory tender offer and planned merger, subject to regulatory approvals.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with limited review by statutory auditors.

• Business operations remain strong, with JB Pharma among the fastest-growing in the Indian pharma market.

• Domestic business grew 14% YoY, maintaining fastest growth among top 25 pharma companies in India.

• Major corporate event: Share purchase agreement with Torrent Pharmaceuticals, leading to a change in promoter and planned amalgamation.

Financial highlights

• Q1 FY26 consolidated revenue rose 9% year-on-year to INR 1,094 crore; net profit up 14% to INR 202 crore.

• Operating EBITDA (excluding ESOP and one-offs) grew 13% to INR 330 crore; margin reached 30.2%, up from 29.0% YoY.

• Gross margin improved to 68.3%, up 210 bps year-on-year.

• Employee benefit and other expenses rose 16% YoY, including INR 15 crore merger-related charges.

• Basic EPS for the quarter: Standalone ₹12.70, Consolidated ₹12.99.

Outlook and guidance

• Board and acquirer approved a scheme of amalgamation, with a share swap ratio of 51:100 (Acquirer:Company), subject to statutory approvals.

• CDMO expected to grow 12%-14% for the year, with average run rate of INR 120 crore in FY26 and INR 140-150 crore in FY27.

• Domestic business projected to grow 12%-14%, outperforming market by 300-350 bps.

• Gross margin guidance maintained at 67% for the full year.

• Operating EBITDA margin guidance remains at 27%-29% for the year, aiming for the upper end.